Opinion|Videos|January 10, 2025
Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences
Author(s)Sikander Ailawadhi, MD
Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma Patients” study examined real-world factors influencing treatment decisions, highlighting the significant role of survivorship burden and patient preferences, and emphasizing how these findings should shape the management strategies for patients with multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the data that were presented at the 2024 ASH Annual Meeting titled in “Survivorship Burden and Patient Preferences Affecting Treatment Choices Among Multiple Myeloma (MM) Patients: Real-World Learnings from a Large, Prospective Study.”
- What was the objective of the study?
- How was this study designed/what methodology was used?
- What results were presented?
- What are your key takeaways from this study, and how do these results impact how you manage patients with MM?
Advertisement
Related to this article
In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.
Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
4
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
5